Statin use linked to few side effects

the popular class of cholesterol-lowering drugs used widely to prevent recurrent heart disease or stroke as well as risk for having a first cardiac or stroke event—appear to cause few side effects, according to new research reported in Circulation: Cardiovascular Quality and Outcomes.

Researchers conducted the largest meta-analysis on statin to date, reviewing data from 135 previous drug studies to evaluate the safety of the seven statins on the market. They concluded "as a class, adverse events associated with statin therapy are not common."

Researchers noted that simvastatin and , the of the brands Zocor and Pravachol, were found to have the best safety profile in the class. This is particularly true when patients were prescribed low to moderate doses of those statins, said Huseyin Naci, M.H.S., the study's lead author and a doctoral candidate at the London School of Economics and Political Science and research fellow at Harvard Medical School's Department of Population Medicine.

Researchers also noted a 9 percent increased risk of diabetes among statin users. But according to a previous landmark study, 250 patients need to be treated with a statin for one case of diabetes to be diagnosed.

"I am concerned that patients may misunderstand this small increase in risk and stop adhering to their medications," Naci said. The proven ability of statins to significantly cut the rate of death and hospitalization in patients who have heart disease outweighs the "small increase in ," he said.

Researchers reviewed trials published between 1985 and early 2013, which included almost 250,000 patients. On average, the trials lasted a bit longer than a year. Some compared one statin to another, while others compared a statin to an inactive placebo, which is often called a sugar pill or .

The study also found that statins were not linked to an increase in . However, the drugs were associated with a typically reversible increase in liver enzymes, which Naci said still resulted in a very low rate of actual liver toxicity in statin .

"Although the benefits of statins clearly outweigh risks at the population level, individualizing such benefits and risks is more difficult," he said. "This brings into sharp focus the importance of identifying the individuals who stand to benefit the most from statin therapy.

Although the risk of developing diabetes is low, what this risk would amount to over time is simply not known based on the existing evidence," Naci said.

add to favorites email to friend print save as pdf

Related Stories

The side effects of statin ads

Mar 07, 2013

Television advertising may drive over-diagnosis of high cholesterol and over-treatment with statins, according to a new study by Dr. Jeff Niederdeppe from Cornell University in the US and colleagues. It appears that a trip ...

Recommended for you

Appropriate use criteria established for pediatric ECHO

10 hours ago

(HealthDay)—Appropriate use criteria have been developed for the initial use of transthoracic echocardiography in outpatient pediatric cardiology. The guidelines were published online Sept. 29 in the Journal of ...

Fish oil supplements don't prevent recurrence of A-fib

Sep 30, 2014

(HealthDay)—High doses of fish oil supplements won't prevent recurrence of atrial fibrillation (AF), Canadian researchers report. The study, funded by the Canadian Institutes for Health Research and the ...

User comments